ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A

Cited by (386)

Items 201–300 of 386

1. PPP2R1A mutations cause ATR inhibitor sensitivity in ovarian clear cell carcinoma
   James Stewart, Dragomir B. Krastev, Rachel Brough, Diana A. Zatreanu, Feifei Song, Joseph S. Baxter, Sandhya Sridhar, Jessica R. Frankum, Asha Konde, William W. Yang et al. · 2025 · Oncogene
2. Genetic alterations and expression characteristics of ARID1A impact tumor immune contexture and survival in early-onset gastric cancer.
   Jun Zou, Wan Qin, Lin Yang, Lulu Wang, Yu Wang, Jianfeng Shen, Wei Xiong, Shiying Yu, Shumei Song, Jaffer A. Ajani et al. · 2020 · PubMed Central
3. The Role of ATR Inhibitors in Ovarian Cancer: Investigating Predictive Biomarkers of Response
   Alice Bradbury, Frank T. Zenke, Nicola J. Curtin, Yvette Drew · 2022 · Cells
4. SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
   Marta J. Llorca-Cardeñosa, Lauren I. Aronson, Dragomir B. Krastev, Jadwiga Nieminuszczy, John J. Alexander, Feifei Song, Małgorzata Dylewska, Ronan Broderick, Rachel Brough, Astrid Zimmermann et al. · 2022 · Cancer Research
5. ATR Inhibitors in Platinum-Resistant Ovarian Cancer
   Siyu Li, Tao Wang, Xichang Fei, Mingjun Zhang · 2022 · Cancers
6. New Insights into Tumor Heterogeneity: A Case of Solid-Oncocytic Epithelial-Myoepithelial Carcinoma of the Parotid Gland Harboring a HRAS and Heterogeneous Terminating ARID1A Mutation
   Niels J. Rupp, Muriel D. Brada, Alena Skálová, Beata Bode, Martina A. Broglie, Grégoire B. Morand, Markus Rechsteiner, Sandra Nicole Freiberger · 2019 · Head and Neck Pathology
7. Exploiting DNA Replication Stress as a Therapeutic Strategy for Breast Cancer
   Jing Zhang, Doug W. Chan, Shiaw‐Yih Lin · 2022 · Biomedicines
8. The role of SWI/SNF chromatin remodelers in the repair of DNA double strand breaks and cancer therapy
   Maria Sadek, Anand Sheth, Grant Zimmerman, Emily Hays, Renier Vélez-Cruz · 2022 · Frontiers in Cell and Developmental Biology
9. The role of molecular testing in pancreatic cancer
   David Bing Zhen, Rachael Ann Safyan, Eric Q. Konick, Ryan Nguyen, C. C. Pritchard, Elena Gabriela Chiorean · 2023 · Therapeutic Advances in Gastroenterology
10. Therapeutic Role of Synthetic Lethality in ARID1A -Deficient Malignancies
    Kyaw Zaw Hein, Bettzy Stephen, Siqing Fu · 2023 · Journal of Immunotherapy and Precision Oncology
11. PTEN deficiency confers colorectal cancer cell resistance to dual inhibitors of FLT3 and aurora kinase A
    Yifan Liu, Eun Ju Yang, Baoyuan Zhang, Zhengqiang Miao, Changjie Wu, Junfang Lyu, Kaeling Tan, Terence Chuen Wai Poon, Joong Sup Shim · 2018 · Cancer Letters
12. Design, synthesis, and biological evaluation of pyrido[3,2-d]pyrimidine derivatives as novel ATR inhibitors
    Yunxin Duan, Lili Zhuang, Yerong Xu, Haodong Cheng, Jiawei Xia, Tao Lu, Yadong Chen · 2023 · Bioorganic Chemistry
13. The Role of the AT-Rich Interaction Domain 1A Gene (ARID1A) in Human Carcinogenesis
    Jing Jing Li, Cheok Soon Lee · 2023 · Genes
14. A novel targeted NGS panel identifies numerous homologous recombination deficiency (HRD)-associated gene mutations in addition to known BRCA mutations
    Anne Vogel, Anna Haupts, Michael T. Kloth, Wilfried Roth, Nils Hartmann · 2024 · Diagnostic Pathology
15. Discovery of Preclinical Candidate AD1058 as a Highly Potent, Selective, and Brain-Penetrant ATR Inhibitor for the Treatment of Advanced Malignancies
    Zhi Liu, Kailong Jiang, Yan Liu, Junfei Li, Siqi Huang, Ping Li, Lei Xu, Xiaomin Xu, Xiaobei Hu, Xia Zeng et al. · 2024 · Journal of Medicinal Chemistry
16. The interplay between chromatin remodeling and DNA double-strand break repair: Implications for cancer biology and therapeutics
    Liu‐Jun He, Jaeyoung Moon, Chenghui Cai, Yalan Hao, Hyorin Lee, Wootae Kim, Fei Zhao, Zhenkun Lou · 2025 · DNA repair
17. Integrative analysis of patient-derived tumoroids and ex vivo organoid modelling of ARID1A loss in bladder cancer reveals therapeutic molecular targets
    Mathijs Scholtes, Maryam Akbarzadeh, Αλέξανδρος Γαλάρας, José Alberto Nakauma‐González, Ameneh Bazrafshan, Vandana Solanki, Bram Torenvliet, Leila Beikmohammadi, Valeria Lozovanu, Shahla Romal et al. · 2025 · Cancer Letters
18. Bromodomain proteins: protectors against endogenous DNA damage and facilitators of genome integrity
    Seo Yun Lee, Jae Jin Kim, Kyle M. Miller · 2021 · Experimental & Molecular Medicine
19. Remodeling of the ARID1A tumor suppressor
    Qingyu Luo, Xiaowei Wu, Zhihua Liu · 2020 · Cancer Letters
20. Integrating Multi-Omics in Endometrial Cancer: From Molecular Insights to Clinical Applications
    Hye Kyeong Kim, Tae Jin Kim · 2025 · Cells
21. PLK1 inhibition selectively induces apoptosis in ARID1A deficient cells through uncoupling of oxygen consumption from ATP production
    Upadhyayula Sai Srinivas, Norbert S. C. Tay, Patrick William Jaynes, Akshaya Anbuselvan, Gokula Krishnan Ramachandran, Joanna D. Wardyn, Michał Marek Hoppe, Phuong Mai Hoang, Yanfen Peng, Sherlly Lim et al. · 2022 · Oncogene
22. Loss of ARID1A expression is associated with DNA mismatch repair protein deficiency and favorable prognosis in advanced stage surgically resected esophageal adenocarcinoma
    Brett Matthew Lowenthal, Katie Sue Nason, Arjun Pennathur, James D. Luketich, Reetesh K. Pai, Jon M. Davison, Changqing Ma · 2019 · Human Pathology
23. TNPO1-mediated nuclear import of ARID1B promotes tumor growth in ARID1A-deficient gynecologic cancer
    Bikang Yang, Jing Chen, Xiao Li, Xueli Zhang, Li-Peng Hu, Shu‐Heng Jiang, Zhigang Zhang, Yincheng Teng · 2021 · Cancer Letters
24. Relationship between cellular morphology and abnormality of SWI/SNF complex subunits in pancreatic undifferentiated carcinoma
    Takeo Yamamoto, Kenichi Kohashi, Yutaka Yamada, Jun Kawata, Kukiko Sakihama, Ryota Matsuda, Yutaka Koga, Shinichi Aishima, Masafumi Nakamura, Yoshinao Oda · 2021 · Journal of Cancer Research and Clinical Oncology
25. Invited Review: Dysregulation of chromatin remodellers in paediatric brain tumours – SMARCB1 and beyond
    Pascal David Johann · 2020 · Neuropathology and Applied Neurobiology
26. Targeting WEE1 to Overcome ARID1A Mutation-Driven Osimertinib Resistance in EGFR-Mutant Lung Cancer
    Koji Fukuda, Shigeki Nanjo, Shinji Takeuchi, Turja Chakrabarti, Tyiesha Sharron Brown, Sharon Wesley Dev Sahadevan, Sachiko Arai, Shigeki Sato, Hiroshi Kotani, Akihiro Nishiyama et al. · 2025 · Journal of Thoracic Oncology
27. CHK1 inhibition increases the therapeutic response to radiotherapy via antitumor immunity in ARID1A-deficient colorectal cancer
    Jhen-Yu Chen, Tao-Wei Ke, Shu‐Fen Chiang, Wei-Ze Hong, Hsin-Yu Chang, Ji An Liang, Yuan‐Yao Tsai, Chi-Hsien Huang, William Tzu‐Liang Chen, K. S. Clifford Chao et al. · 2025 · Cell Death and Disease
28. Targeting DNA repair mechanisms in cancer therapy: the role of small molecule DNA repair inhibitors
    Seula Jeong, Yuheon Chung, Soomin Heo, Kyungjae Myung · 2025 · NAR Cancer
29. Emerging target discovery and drug repurposing opportunities in chordoma
    Daniel M. Freed, Josh Sommer, Nindo B. Punturi · 2022 · Frontiers in Oncology
30. Increased genomic instability and reshaping of tissue microenvironment underlie oncogenic properties of Arid1a mutations
    Alessandro D’Ambrosio, Davide Bressan, Elisa Ferracci, Francesco Giuseppe Carbone, Patrizia Mulé, Federico Rossi, Caterina Barbieri, Elisa Sorrenti, Gaia Fiaccadori, Thomas Detone et al. · 2024 · Science Advances
31. Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated disease
    Fergus Keane, Joanne F. Chou, Henry S. Walch, Joshua David Schoenfeld, Anupriya Singhal, Darren Cowzer, Emily C. Harrold, Catherine Anne O'Connor, Wungki Park, Anna M. Varghese et al. · 2024 · JNCI Journal of the National Cancer Institute
32. A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors
    Gregory Michael Cote, Bose S. Kochupurakkal, Khanh T Do, Andrea J. Bullock, Michael L. Cheng, Alona Muzikansky, Daniel E. McLoughlin, James M. Cleary, Xin Gao, Aparna R. Parikh et al. · 2024 · Clinical Cancer Research
33. KLF5 loss sensitizes cells to ATR inhibition and is synthetic lethal with ARID1A deficiency
    Samah W. Awwad, Colm Doyle, Josie Coulthard, Aldo S. Bader, Nadia Gueorguieva, Simon Lam, Vipul Gupta, R. Belotserkovskaya, Tuan-Anh Tran, Shankar Balasubramanian et al. · 2025 · Nature Communications
34. Characterising acquired resistance to erlotinib in non-small cell lung cancer patients
    Niki Karachaliou, Jordi Codony‐Servat, Jillian Wilhelmina Paulina Bracht, Masaoki Ito, Martyna Filipska, Carlos Pedraz‐Valdunciel, Imane CHAIB-OUKADOUR, Jordi Bertrán-Alamillo, Andrés Felipe Cardona, Miguel Ángel Molina‐Vila et al. · 2019 · Expert Review of Respiratory Medicine
35. Targeting the BAF complex in advanced prostate cancer
    Andrew Hartley, Hing Y. Leung, Imran Ahmad · 2020 · Expert Opinion on Drug Discovery
36. PARP inhibition-associated heterochromatin confers increased DNA replication stress and vulnerability to ATR inhibition in SMARCA4-deficient cells
    Kimiyoshi Yano, Megumi Kato, Syoju Endo, Taichi Igarashi, Ryoga Wada, Takashi Kohno, Astrid Zimmermann, Heike Dahmen, Frank T. Zenke, Bunsyo Shiotani · 2025 · Cell Death Discovery
37. ARID1A mutation in blastic plasmacytoid dendritic cell neoplasm
    Lei Wang, Min Yang, Xiang Zhang, Chunmei Yang, Xin Huang, Zhaoming Wang, Jie Jin · 2017 · Haematologica
38. Unveiling Commonalities: Exploring Shared Characteristics in Clear-Cell Carcinomas of the Gynecologic Tract
    Félix Blanc‐Durand, Natalie Y.L. Ngoi, Diana Gkeok Stzuan Lim, David S.P. Tan · 2024 · Clinical Cancer Research
39. Clearer Horizons: The latest advances in clear cell ovarian cancer treatment
    Félix Blanc‐Durand, Natalie Y.L. Ngoi, Diana Gkeok Stzuan Lim, Isabelle Laure Ray-Coquard, David S.P. Tan · 2025 · Cancer Treatment Reviews
40. Treatment for ovarian clear cell carcinoma with combined inhibition of WEE1 and ATR
    Wenwen Chien, Jeffrey W Tyner, Sigal Gery, Yueyuan Zheng, Liyan Li, Mohan Shankar Gopinatha Pillai, Chehyun Nam, Neil A. Bhowmick, De‐Chen Lin, Harold Phillip Koeffler · 2023 · Journal of Ovarian Research
41. Exploiting the DNA Damage Response for Prostate Cancer Therapy
    Travis H. Stracker, Oloruntoba Ismail Osagie, Freddy E. Escorcia, Deborah E. Citrin · 2023 · Cancers
42. Identifying Cell Cycle Modulators That Selectively Target ARID1A Deficiency Using High-Throughput Image-Based Screening
    Lihong Zhang, Jianfeng Shen, Yuping Yin, Yang Peng, Lulu Wang, Hui-Ju Hsieh, Qian Shen, Powel H. Brown, Kaixiong Tao, Iván P. Uray et al. · 2017 · SLAS DISCOVERY
43. Discovery of the Clinical Candidate YY2201 as a Highly Potent and Selective ATR Inhibitor
    Meng Yin Wu, Xiaofang Chen, Haoran Wang, Chang Li, Wenjing Liu, Xiao Zheng, Jingxin Yang, Xin Ye, Yali Weng, Tianyun Fan et al. · 2025 · Journal of Medicinal Chemistry
44. SMARCA4 Loss Increases RNA Polymerase II Pausing and Elevates R-Loops to Inhibit BRCA1-Mediated Repair in Ovarian Cancer
    Xianbing Zhu, Zheng Fu, Giulio Aceto, Jonathan R. St‐Germain, Kexin Liu, Azadeh Arabzadeh, Yuxuan Qi, Yibo Xue, Leora Witkowski, Elise Graulich et al. · 2025 · Cancer Research
45. Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor
    Diego Daniel Manavella, Blair C. McNamara, Justin A. Harold, Stefania Bellone, Tobias M.P. Hartwich, Yang Yang‐Hartwich, Levent Mutlu, Margherita Zipponi, Cem Demirkiran, Miguel Skyler Z. Verzosa et al. · 2022 · Gynecologic Oncology
46. Novel agents for mantle cell lymphoma: molecular rational and clinical data
    Clémentine Sarkozy, Vincent Ribrag · 2020 · Expert Opinion on Investigational Drugs
47. Genomic Instability and Replicative Stress in Multiple Myeloma: The Final Curtain?
    Oronza Antonietta Botrugno, Giovanni Tonon · 2021 · Cancers
48. AURKA inhibition shows promise as a therapeutic strategy for ARID1A-mutant colorectal cancer
    Rongsheng Qin, Chun-Tao Li, Fei Chen, Shu Luo, Chao Wang, Jie Li, Shan Xu, MingWei Kang, Hao-Wen Hu · 2024 · Discover Oncology
49. Controversies in the management of clear cell carcinoma of the uterus and ovary
    Manavi Sachdeva, Félix Blanc‐Durand, David S.P. Tan · 2025 · International Journal of Gynecological Cancer
50. Targeting base excision repair in precision oncology
    Nicola Pietro Montaldo, Hilde Loge Nilsen, Diana Lilian Bordin · 2025 · DNA repair
51. ARID1A deficiency promotes progression and potentiates therapeutic antitumour immunity in hepatitis B virus-related hepatocellular carcinoma
    Tao Xing, Li Li, Xiaosong Rao, Jing Zhao, Yiran Chen, Gaoda Ju, Yaping Xu, Xuan Gao, Guilan Dong, Xuefeng Xia et al. · 2024 · BMC Gastroenterology
52. Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression
    Matthew L. Hemming, Patrick D. Bhola, Michael A. Loycano, Justin A. Anderson, Madeleine L. Taddei, Leona A. Doyle, Elizaveta Lavrova, Jessica L. Andersen, Kelly S. Klega, Morgan R. Benson et al. · 2022 · Clinical Cancer Research
53. State of the Biomarker Science in Ovarian Cancer: A National Cancer Institute Clinical Trials Planning Meeting Report
    Josée-Lyne Ethier, Katherine Cynthia Fuh, Rebecca Christian Arend, Gottfried E. Konecny, Panagiotis A. Konstantinopoulos, Kunle O. Odunsi, Elizabeth M. Swisher, Elise C. Kohn, Dmitriy Zamarin · 2022 · JCO Precision Oncology
54. You won't believe this old test … that does cheap single‐cell mutation detection
    Martin Köbel, Michael S. Anglesio, James D. Brenton · 2018 · The Journal of Pathology Clinical Research
55. NEMO is essential for directing the kinases IKKα and ATM to the sites of DNA damage
    Josune Alonso‐Marañón, Laura Solé, Daniel Alvarez Villanueva, María Maqueda, Teresa Lobo‐Jarne, Ángela Montoto, José Yélamos, Eva Borràs, Leire Uraga, Christopher Hooper et al. · 2025 · Science Signaling
56. ARID1A: gene, protein, and function in endometrial cancer
    Savannah E. LaBuda, Russell R. Broaddus, Andrew B. Gladden · 2025 · Oncogene
57. ARID1A in Gynecologic Precancers and Cancers
    Jaida E. Morgan, Nishah Jaferi, Zainab Shonibare, Gloria Shining Huang · 2024 · Reproductive Sciences
58. Advances in the study of the role of high-frequency mutant subunits of the SWI/SNF complex in tumors
    Jiumei Zhao, Jing Zhu, Yu Tang, Kepu Zheng, Ziwei Li · 2024 · Frontiers in Oncology
59. The diagnostic role of PTEN and ARID1A in serous effusions
    Ben Davidson, Maurizio Pinamonti, Dolors Cuevas, Arild Holth, Pio Zeppa, Thomas Hager, Jeremias Wohlschlaeger, Martin Tötsch · 2017 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
60. Control of the Cell Cycle
    Marcos Malumbres · 2020 · Elsevier eBooks
61. New molecular tumor markers for endometrial cancer.
    Fumitaka Numa, Kenji Umayahara, Yutaka Suehiro, Yoshinori Suminami, Atunori Oga, Kohsuke Sasaki, Hiroyuki Kato · 2001 · PubMed
62. Precision Medicine for Gastric Cancer: Current State of Organoid Drug Testing
    Tharindie N. Silva, Josephine A. Wright, Daniel L. Worthley, Susan Lesley Woods · 2024 · Organoids
63. Swinging the SWI/SNF complexes for cancer therapy
    Hongyan Jing, Xi Zhang, Linghua Meng · 2025 · Trends in Pharmacological Sciences
64. Targeting DNA Damage Repair Pathways Beyond PARP Inhibition
    Eve Merry, Charlie Gourley · 2025 · Targeted Oncology
65. Loss of ARID1A accelerates prostate tumourigenesis with a proliferative collagen-poor phenotype through co-operation with AP1 subunit cFos
    Andrew Hartley, Laura C.A. Galbraith, Robin Shaw, Amy J. Tibbo, Rajan Veeratterapillay, Laura Wilson, Rakesh Heer, Karen Blyth, Hing Y. Leung, Imran Ahmad · 2025 · British Journal of Cancer
66. Bevacizumab in frontline chemotherapy improved the survival outcome for advanced ovarian clear cell carcinoma: a multicenter retrospective analysis
    Shinichi Tate, Toshiyuki Seki, Kyoko Nishikimi, Youichi Unno, Mizue Itoi, Sadatomo Ikeda, Nobuhisa Yoshikawa, Hidehiko Akashi, Eitaro Suzuki, Naotake Tanaka et al. · 2025 · Journal of Gynecologic Oncology
67. SWI/SNF Alterations in Squamous Bladder Cancers
    Fabian Achenbach, Michael Rose, Nadina Ortiz‐Brüchle, Lancelot Seillier, Ruth Knüchel, Veronika Weyerer, Arndt Hartmann, Ronja Morsch, Angela Maurer, Thorsten Ecke et al. · 2020 · Genes
68. Remarkable Response to the Triplet Combination of Olaparib with Pembrolizumab and Bevacizumab in the Third-Line Treatment of an Ovarian Clear Cell Carcinoma Patient with an ARID1A Mutation: A Case Report
    Yingchao Zhao, Yao Jiang · 2022 · OncoTargets and Therapy
69. Pathway-based signatures predict patient outcome, chemotherapy benefit and synthetic lethal dependencies in invasive lobular breast cancer
    John J. Alexander, Koen Schipper, Sarah Nash, Rachel Brough, Harriet Kemp, Jacopo Iacovacci, Clare M. Isacke, Rachael Natrajan, Elinor J. Sawyer, Christopher J. Lord et al. · 2024 · British Journal of Cancer
70. Computational Approaches to Identify Genetic Interactions for Cancer Therapeutics
    Graeme Benstead-Hume, Sarah K. Wooller, Frances M. G. Pearl · 2017 · Berichte aus der medizinischen Informatik und Bioinformatik/Journal of integrative bioinformatics
71. Synthetic Lethality Is a Novel and Potential Paradigm for Precision Medicine in Advanced Hepatocellular Carcinoma
    Mingyu Chen, Xiujun Cai · 2019 · Liver Cancer
72. Perspective on the Use of DNA Repair Inhibitors as a Tool for Imaging and Radionuclide Therapy of Glioblastoma
    Liesbeth Everix, Shankari Nair, Cathryn H. S. Driver, Ingeborg Goethals, Mike Machaba Sathekge, Thomas Ebenhan, Charlot Vandevoorde, Julie Bolcaen · 2022 · Cancers
73. Efficacy of the ATR Inhibitor Ceralasertib in Patients with ARID1A-Deficient Gynecologic and Other Solid Tumor Malignancies
    Xiaolin Zhu, Edwin Alexander Alvarez, Sarah E. Umetsu, Jocelyn S. Chapman, Lee-may Chen, Stefanie M. Ueda, Suzannah Henderson, Phuong Nguyen, Susan Calabrese, Jacky Russell et al. · 2026 · Clinical Cancer Research
74. Targeting the alterations of ARID1A in pancreatic cancer: tumorigenesis, prediction of treatment, and prognostic value.
    Ruichao Li, Guangbing Xiong, Jun Zhao, Lin Yang · 2022 · PubMed Central
75. Targeting ATR in Cancer Medicine
    Carolina Salguero, Christian Valladolid, Helen M.R. Robinson, Graeme C.M. Smith, Timothy Anthony Yap · 2023 · Cancer treatment and research
76. Semi-mechanistic efficacy model for PARP + ATR inhibitors—application to rucaparib and talazoparib in combination with gartisertib in breast cancer PDXs
    Claire C. Villette, Nathalie Dupuy, Frances A. Brightman, Astrid Zimmermann, Floriane Lignet, Frank T. Zenke, Nadia Terranova, Jayaprakasam Bolleddula, Samer El Bawab, Christophe Chassagnole · 2025 · British Journal of Cancer
77. DNA replication stress stratifies prognosis and enables exploitable therapeutic vulnerabilities of HBV-associated hepatocellular carcinoma: An in-silico precision oncology strategy
    Xiaofan Lu, Jialin Meng, Haitao Wang, Yujie Zhou, Jian‐Guo Zhou, Xinjia Ruan, Yi Chen, Yuqing Ye, Liwen Su, Xiaole Fan et al. · 2023 · The Innovation Medicine
78. An Exploration of Organoid Technology: Present Advancements, Applications, and Obstacles
    Isha Mishra, Komal Gupta, Raghav Mishra, Kajal Chaudhary, Vikram Sharma · 2023 · Current Pharmaceutical Biotechnology
79. BaCoN (Balanced Correlation Network) improves prediction of gene buffering
    Thomas Rohde, Talip Yasir Demirtas, Sebastian Süsser, Angela Helen Shaw, Manuel Kaulich, Maximilian Billmann · 2025 · Molecular Systems Biology
80. Recent Therapies and Biomarkers in Mucinous Ovarian Carcinoma
    Grzegorz Przywara, Oliwia Biegańska, Emilia Biczak, Aleksander Białoń, Dominik Fidorowicz, Alicja Dankowska, Zofia Łapińska, Julita Kulbacka · 2025 · Cells
81. Targeting WEE1 in ARID1A/TP53 Concurrent Mutant Colorectal Cancer by Exploiting R‐Loop Accumulation and DNA Repair Deficiencies
    Chi Zhang, Yanjing Zhu, Luoyan Ai, Jingyuan Wang, Shan Yu, Yichen Wang, Xiaojing Xu, Mengling Liu, Yiyi Yu, Meng-Xuan Zhu et al. · 2025 · Advanced Science
82. Deciphering the regulatory mechanisms and biological implications of ARID1A missense mutations in cancer
    Fang Liu, Jun Ying, Kai Yang, Xinyuan Xiong, Nan Yang, Shu Wang, Wenzhen Zhao, Huiqin Zhu, Ming Yu, Jun Wu et al. · 2024 · Cell Reports
83. Arid1a deficiency sensitises pancreatic cancer to fatty acid synthase inhibition
    Tzu‐Lei Kuo, Ya‐Chin Hou, Yan‐Shen Shan, Li‐Tzong Chen, Wen‐Chun Hung · 2025 · Clinical and Translational Medicine
84. Clinicopathologic and Genomic Characterization of SMARCA4-Deficient Carcinoma of the Gallbladder
    Qiqi Jia, Yi-Shan Chen, Yuyao Pan, Shan Gao, Xiaoyun Wei, Yangyang Fan, Pengjun Li, Zhe Yang, Jun Pu, Pengfei Nan et al. · 2025 · Modern Pathology
85. Synthetic lethality in personalized cancer therapy
    Ying Ki Pang, Meng Cheng, Mu Chen, Kaijun Zhao, Yuanyuan Yin, Min Liu, Jing Zhang, Chunlong Zhong · 2022 · Genome Instability & Disease
86. Genome-Wide CRISPR Screen Identifies KEAP1 Perturbation as a Vulnerability of ARID1A-Deficient Cells
    Louis-Alexandre Fournier, Forouh Kalantari, James P. Wells, Joon S. Lee, Genny Trigo‐Gonzalez, Michelle Moksa, T Smith, Justin White, Alynn Shanks, Siyun Wang et al. · 2024 · Cancers
87. The clinical signiicance of ARID1A mutations in gastric cancer patients
    Chia‐Hung Wu, Chien-Hsun Tseng, Kuo‐Hung Huang, Wen‐Liang Fang, Ming‐Huang Chen, Anna Fen–Yau Li, Chew-Wun Wu · 2020 · Formosan Journal of Surgery
88. Exploiting Cancer Synthetic Lethality in Cancer—Lessons Learnt from PARP Inhibitors
    Stephen J. Pettitt, Colm J. Ryan, Christopher J. Lord · 2023 · Cancer treatment and research
89. ARID1A Governs Genomic Stability and Proliferation in SCLC via c-MYC/PARP1 Suppression Driving Vulnerability to BET Inhibitors
    Guozhen Cao, Lu Ma, Xueqin Dai, Peng Hou, Xinhuang Yao, Gongfeng Li, Jiahui Zhang, Ceshi Chen, Wenchu Lin · 2025 · Research
90. Chromatin remodeling complexes: architects influencing breast cancer progression
    Octavianus Giovani, Grace S. Eckersley, Hayden R. Jones, Sankari Nagarajan · 2025 · Frontiers in Cell and Developmental Biology
91. Multidimensional OMICs reveal ARID1A orchestrated control of DNA damage, splicing, and cell cycle in normal‐like and malignant urothelial cells
    R. Schlosser, Florian Krumbach, Eyleen Corrales, Geoffroy Andrieux, Christian Preisinger, Franziska Liss, Alexandra Golzmann, Melanie Boerries, Kerstin Becker, Ruth Knüchel et al. · 2025 · Molecular Oncology
92. Role of Patient-Derived Tumor Organoids in Advanced Cancer Research
    Taku Sato · 2025 · Journal of Nippon Medical School
93. Grand Challenges in Molecular Medicine for Disease Prevention and Treatment Through Cyclical Innovation
    Masuko Katoh, Masaru Katoh · 2021 · Frontiers in Molecular Medicine
94. A novel mutation in SMARCB1 associated with adult Coffin-Siris syndrome and meningioma
    Zhenglong Guo, Jie Bai, Yang Liu, Xianwei Zhang, Wenke Yang, Jinming Wang, Yuwei Zhang, Hai Xiao, Bingtao Hao, Shixiu Liao · 2024 · Acta Biochimica et Biophysica Sinica
95. Targeting the Ataxia Telangiectasia and Rad3 Signaling Pathway to Overcome Chemoresistance in Cancer
    Marwan Kwok, Tatjana Stanković · 2018 · Elsevier eBooks
96. Conceptual frameworks of synthetic lethality in clear cell carcinoma of the ovary (Review)
    Hiroshi Kobayashi, Naoki Kawahara, Kenji Ogawa, Yuki Yamada, Kana Iwai, Emiko Niiro, Sachiko Morioka · 2018 · Biomedical Reports
97. AT-rich interactive domain1A determines sensitivity to oxaliplatin in gastric cancer cells
    Qing Lin Liu, Qing-Qing Weng, Song-Fei Shen, Tao Jiang, Zhangchi Pan, Mengxin Lin, Yanqin Lan, Yao Wang, Qiang Chen, Chunmei Shi · 2020 · Translational Cancer Research
98. PLK1 inhibition selectively kills ARID1A deficient cells through uncoupling of oxygen consumption from ATP production
    Upadhyayula Sai Srinivas, Gokula Krishnan Ramachandran, Joanna D. Wardyn, Michał Marek Hoppe, Yanfen Peng, Sherlly Lim, May Yin Lee, Praveen C. Peethala, Ömer An, Akshay Shendre et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
99. Elimusertib outperforms standard of care chemotherapy in preclinical patient-derived pediatric solid tumor models
    Fabian F. Pusch, Heathcliff Dorado García, Robin Xu, Dennis Gürgen, Yi Bei, Lotte Brückner, Claudia Röefzaad, Jennifer von Stebut, Victor Bardinet, Rocío Chamorro González et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
100. Association of ATM and ARID1A in gastric carcinoma
     Inwoo Hwang, Somin Lee, Yuyeon Kim, Deok Geun Kim, So Young Kang, Soomin Ahn, Jeeyun Lee, Kyoung‐Mee Kim · 2024 · Pathology - Research and Practice